Synthesis and characterization of an MRI Gd-based probe designed to target the translocator protein

Erika Cerutti,a Annelaure Damont,b Frédéric Dollé,b Simona Baroni and Silvio Aimea∗

DPA-713 is the lead compound of a recently reported pyrazolo[1,5-a]pyrimidineacetamide series, targeting the translocator protein (TSPO 18 kDa), and as such, this structure, as well as closely related derivatives, have been already successfully used as positron emission tomography radioligands. On the basis of the pharmacological core of this ligands series, a new magnetic resonance imaging probe, coded DPA-C6-(Gd)DOTAMA was designed and successfully synthesized in six steps and 13% overall yield from DPA-713. The Gd-DOTA monoamide cage (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) represents the magnetic resonance imaging reporter, which is spaced from the phenylpyrazolo[1,5-a]pyrimidineacetamide moiety (DPA-713 motif) by a six carbon-atom chain. DPA-C6-(Gd)DOTAMA relaxometric characterization showed the typical behavior of a small-sized molecule (relaxivity value: 6.02 mM−1 s−1 at 20 MHz). The good hydrophilicity of the metal chelate makes DPA-C6-(Gd)DOTAMA soluble in water, affecting thus its biodistribution with respect to the parent lipophilic DPA-713 molecule. For this reason, it was deemed of interest to load the probe to a large carrier in order to increase its residence lifetime in blood. Whereas DPA-C6-(Gd)DOTAMA binds to serum albumin with a low affinity constant, it can be entrapped into liposomes (both in the membrane and in the inner aqueous cavity). The stability of the supramolecular adduct formed by the Gd-complex and liposomes was assessed by a competition test with albumin. Copyright © 2013 John Wiley & Sons, Ltd.

Keywords: NMR; 1H; MRI; contrast agents; relaxometry; Gd-complexes; DPA-713; TSPO

Introduction

The translocator protein (TSPO-18 kDa), formerly known as peripheral benzodiazepine receptor,[1,2] is a five-transmembrane protein[3,4] localized primarily on the outer mitochondrial membrane.[1,5] TSPO is expressed in many organs, but it is expressed at the highest level in steroidogenic cells, where TSPO is involved in the translocation of cholesterol from the outer to the inner mitochondrial membranes. TSPO is also located in the central nervous system where it is usually expressed in microglia[4,5] and in some neuronal cell types.[6–9] Following neuronal injury, TSPO expression is dramatically increased, in particular, in the case of Alzheimer disease and multiple sclerosis.[10,11] Microglia are extremely sensitive toward alterations due to neuronal injury. Until now, positron emission tomography has been the most used medical imaging technique in the study of how microglia are involved in degenerative diseases. Different TSPO targeting molecules have been synthesized over the past two decades. They belong to different chemical classes,[12–14] but the most promising one is the 2-phenylpyrazolo[1,5-a]pyrimidineacetamide series[15,16], which includes, among others, the two following radio-tracers: [11C]DPA-713[17–19] and [18F]FDPA-714.[20–25,27,28]

Magnetic resonance imaging (MRI) is a non-invasive technique that allows morphology, physiology and metabolism visualization in vivo. MRI images deal with water 1H proton spatial localization, whose intensity is sufficiently high, thanks to the high concentration of water in living organisms. The main advantage of this technique is its superb spatial resolution (in ordinary image acquisition, a resolution of 100 μm is attained), but its major drawback is represented by the low sensitivity of its probes.[28]

A novel MRI Gd-based probe has therefore been designed, combining the pharmacological properties of the DPA-713 core with a gadolinium-dedicated (DOTA) chelator. The conjugation site was selected on the basis of previous SAR studies having shown that chemical flexibility was permitted at the para position of the phenyl ring.[29] A spacer of six carbon atoms was moreover introduced to minimize the steric hindrance of the DOTA cage at the interaction site of the molecule with TSPO. As the development of an MRI targeting agent requires systems that remain in circulation for a long time, the interaction of DPA-C6-(Gd)DOTAMA with human serum albumin (HSA) and its incorporation into liposomes have been explored. Moreover, the latter systems can act as carriers for a great number of imaging reporter units thus offering a route to overcome the sensitivity issue associated to MR applications.

Magn. Reson. Chem. 2013, 51, 116–122

Copyright © 2013 John Wiley & Sons, Ltd.
Results and Discussion

DPA-C6-(Gd)DOTAMA (1) was synthesized in six steps from DPA-713 and obtained in 13% overall and non-optimized yield (Scheme 1). Briefly, DPA-713, as starting material, was synthesized according to literature procedures.\textsuperscript{[17]} O-demethylation of DPA-713 was carried out with a 1 M solution of BBr\textsubscript{3} in dichloromethane at low temperature (from \(-60\) to \(-20^\circ\)C) affording the corresponding phenol 2 (DPA-OH) in high yield (95%).\textsuperscript{[20]} The aminohexyl spacer was introduced into the structure by coupling the DPA-skeleton 2 with 6-(Boc-amino)hexan-1-ol activated as a sulfonate (synthesized as described in the experimental part) in DMSO at 50°C in the presence of NaOH as a base, to afford product 3 in moderate yield (63%). The Boc protecting group was removed using trifluoroacetic acid in dichloromethane, giving the free amine (4) in 80% yield. Coupling of 4 with DOTA(tBu)\textsubscript{3}\textsuperscript{[30]} was carried out in the presence of TBTU and DIPEA in DMF yielding the DOTAMA derivative 5 in 80% yield. Tert-Butyl groups were then removed using trifluoroacetic acid to afford 6 (DPA-C\textsubscript{6}-DOTAMA) in 33% yield after chromatography purification. The ligand complexation was carried out by stoichiometric addition of GdCl\textsubscript{3} maintaining the pH at 6.5 by addition of a 0.1 N aqueous NaOH solution.

Relaxometric characterization of DPA-C6-(Gd)DOTAMA (1)

The relaxivity of 1 (i.e. the change of the water proton relaxation rate in the presence of the paramagnetic complex at 1 mM concentration) measured at 20 MHz and 20°C was 6.02 mM\textsuperscript{-1}s\textsuperscript{-1}. This value was slightly higher than that reported in literature\textsuperscript{[31]} for the parent Gd-DOTAMA complex \((r_{1p} = 4.7\) mM\textsuperscript{-1}s\textsuperscript{-1})\textsuperscript{[31]}. The nuclear magnetic resonance dispersion (NMRD) profile was also acquired (Figure 1) and found to show the typical behavior of small gadolinium complexes.

The NMRD data were fitted to the values calculated on the basis of the established paramagnetic relaxation theory,\textsuperscript{[32]} and the obtained values are reported in Table 1 together with the corresponding ones of the parent Gd-DOTAMA-C\textsubscript{6}-OH. Going from Gd-DOTAMA-C\textsubscript{6}-OH to 1, the increased molecular weight is responsible for the markedly longer molecular re-orientational time \(\tau_r\), which in turn is the main determinant of the increase of the observed relaxivity.

Interaction of DPA-C6-(Gd)DOTAMA (1) with HSA

Human serum albumin is the most abundant protein in blood and often acts as carrier for metabolites, nutrients and drugs. The lipophilicity of the DPA-713 moiety anticipates the possible binding of 1 to HSA. Binding parameters (the affinity constant \(K_A\) and the relaxivity of supramolecular adduct \(r_{1p}^{\text{bound}}\)) were determined using the proton relaxation enhancement (PRE) method.\textsuperscript{[33]} The experimental procedure consists of carrying out a titration in a fixed quantity of Gd-complex (0.19 mM) is titrated with aqueous solution of DPA-C\textsubscript{6}-(Gd)DOTAMA (1) and human serum albumin adduct \(\text{HSA}\) at 25°C and pH = 7.4.

The obtained \(K_A\) value demonstrates that there is a relatively weak interaction between 1 and albumin. The calculated \(r_{1p}^{\text{bound}}\) is markedly higher than the \(r_{1p}\) of the free DPA-C\textsubscript{6}-(Gd)DOTAMA (1), in accordance with the formation of the adduct with albumin that is characterized by a markedly slower tumbling rate.

The NMRD profile of a solution containing DPA-C\textsubscript{6}-(Gd) DOTAMA (1) and HSA in ca. 1:1 ratio (0.19 mM of 1 and 0.2 mM of HSA) was acquired (data not shown). On the basis of the previously mentioned reported results, compound 1 is only in part bound to HSA. From the knowledge of the affinity constant \((K_A)\) and the millimolar relaxivity of the bound fraction \((r_{1p}^{\text{bound}})\), it

\begin{figure}
\centering
\includegraphics[width=\textwidth]{Figure1}
\caption{1/T\textsubscript{1} nuclear magnetic resonance dispersion profile of 1 mM aqueous solution of DPA-C\textsubscript{6}-(Gd)DOTAMA (a) and human serum albumin adduct (b) at 25°C and pH = 7.4.}
\end{figure}

\begin{table}
\centering
\begin{tabular}{|c|c|c|c|c|c|c|}
\hline
& \(\Delta^2\) & \(\tau_r\) & \(\tau_m\) & \(q\) & \(r_{1p}\) & \(\text{ps}\) & \(\text{mm}^2\text{s}^{-1}\) & \(\text{mm}^{-1}\text{s}^{-1}\) \\
\hline
DPA-C\textsubscript{6}-(Gd)DOTAMA (1) & 2.65 & 27 & 114 & 1.4 & 1 & 6.02 & \\
Gd-DOTAMA-C\textsubscript{6}-OH & 1.4 & 40 & 70 & 1.3 & 1 & 4.7 & \\
\hline
\end{tabular}
\caption{Table 1. Best fitting parameters for from the analysis of the nuclear magnetic resonance dispersion profile of 1}
\end{table}

\footnote{\textsuperscript{a} Measured at 25°C at 20 MHz.}

\begin{scheme}
\centering
\includegraphics[width=\textwidth]{Scheme1}
\caption{Scheme 1. Synthesis of DPA-C\textsubscript{6}-(Gd)DOTAMA. (i) BBr\textsubscript{3}, CH\textsubscript{2}Cl\textsubscript{2} anhydr., \(-60°C\) to \(-20°C\), 5 h; (ii) 6-(\textsuperscript{\text{t}}-tert-butylcarboxy)aminohexyl 4-methylbenzenesulfonate, NaOH, DMSO, 50°C, overnight; (iii) TFA, CH\textsubscript{2}Cl\textsubscript{2}, RT, 24 h; (iv) DOTAm(Bu\textsubscript{3}), TBTU, DIPEA, DMF, RT, 24 h; (v) TFA, CH\textsubscript{2}Cl\textsubscript{2}, RT, 24 h; (vi) GdCl\textsubscript{3} \times 6H\textsubscript{2}O, pH = 6.5, RT.}
\end{scheme}
has been possible to quantify as 68% the percentage of compound 1 bound to HSA under the applied 1:1 ratio. From these data, the NMRD profile for the fraction of DPA-C₆-(Gd)DOTAMA bound to HSA has been calculated (Figure 1), and the high field relaxation values fitted according to the theory of paramagnetic relaxation enhancement. The values obtained for the relevant parameters are reported in Table 2.

On going from the free complex (1) to the adduct with HSA, a high relaxation peak centered at ca. 40 MHz is observed for the latter species indicative of a relaxivity domain determined by high relaxivity peak centered at ca. 40 MHz is observed for the parameters are reported in Table 2.

**Entrapment of DPA-C₆-(Gd)DOTAMA (1) in liposomes**

Entrapment into liposomes of DPA-C₆-(Gd)DOTAMA (1) has been taken into account to increase the circulation lifetime and to pursue a slow release of the compound of interest. Two types of liposome have been prepared, namely LP1 and LP2. Both liposomes were prepared by means of the thin film hydration method. The latter procedure consists of two key steps, namely a first step that leads to the lipidic film that is hydrated (second step) with a saline buffer solution (HEPES/NaCl mole ratio 1/6.75). Vesicles were formulated by using 72% (for LP1) or 87% (for LP2) of POPC (1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine), 10% of cholesterol and 3% of DSPE-PEG-methoxy-2000 (1,2-distearyl-sn-glycerol-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt)). For LP1, 15% of 1 was mixed with the lipidic components to yield the lipidic film. In LP2, 1 was dissolved in the hydration solution (20 mM). By the latter procedure, DPA-C₆-(Gd)DOTAMA is encapsulated in the aqueous cavity of the liposome. The mean hydrodynamic diameters of the liposomes were determined by dynamic light scattering. They were found to be very similar thus showing that the methodology of preparation is not as relevant as the formulation in determining the final size of the vesicles (Table 3).

The relaxivity values, measured at 25 °C at 20 MHz, were found to be 9.69 and 7.85 mM⁻¹ s⁻¹ for LP1 and LP2, respectively. These values are higher than the value obtained for free 1, as consequence of the interaction with the liposome membrane. Overall, the observed relaxation enhancement is lower than the one usually observed for amphiphilic Gd complexes interacting with a liposomal membrane. For both types of liposomes, one may think that an equilibrium is occurring in the inner cavity for which DPA-C₆-(Gd)DOTAMA distributes between the inner membrane layer and the aqueous solution. Thus, the NMRD profiles of both liposomes were analyzed taking into account either the contribution due to 1 ‘free’ (in the inner cavity) and the one due to 1 incorporated in the membrane. Equation (1) has been used:

$$r_{1p} = X^{\text{free}} r_{1p}^{\text{free}} + X^{\text{bound}} r_{1p}^{\text{bound}}$$

where $X^{\text{bound}}$ and $X^{\text{free}}$ are the molar fraction of 1 that is bound or not bound to the liposome’s membrane, $r_{1p}^{\text{free}}$ is the relaxivity value of 1 (6.02 mM⁻¹ s⁻¹) and $r_{1p}^{\text{bound}}$ is the relaxivity value of the adduct DPA-C₆-(Gd)DOTAMA-liposome. We fixed the latter value to 16 mM⁻¹ s⁻¹, that is the relaxivity value for analogous Gd-DOTAMA system incorporated in liposome’s membrane previously investigated in our laboratory. Table 3 lists the Liposome formulations and main parameters.

### Table 2. Best fitting parameters for DPA-C₆-(Gd)DOTAMA/HSA

| DPA-C₆-(Gd)DOTAMA/HSA | Δ² (10¹⁹ s⁻²) | τ₀ (ps) | τᵣ (ps) | τᵣm (μs) | q |
|-----------------------|--------------|---------|---------|----------|---|
| DPA-C₆-(Gd)DOTAMA/HSA | 1.15         | 24      | 59 000  | 1.1 1    |   |

### Table 3. Liposome formulations and main parameters

| Membrane | Molar ratio | Cavity         | Dimension (nm) | $r_{1p}$ (mM⁻¹ s⁻¹) a |
|----------|-------------|----------------|----------------|----------------------|
| LP1      | POPC 72%    | Saline buffer  | 151            | 9.69                 |
|          | Chol 10%    |                |                |                      |
|          | DSPE-PEG-methoxy 2000 3% |                |                |                      |
|          | DPA-C₆-(Gd)DOTAMA 15% |                |                |                      |
| LP2      | POPC 87%    | DPA-C₆-(Gd)DOTAMA 20 mM | 149            | 7.85                 |
|          | Chol 10%    |                |                |                      |
|          | DSPE-PEG-methoxy 2000 3% |                |                |                      |

a Measured at 25 °C at 20 MHz.
values for the two types of liposomes have been extracted (Figure 3).

The calculated NMRD profiles of the bound fraction were then fitted as earlier recalled,\cite{12} and the best fitting values for the relevant parameters are reported in Table 4.

The 'humps' at high magnetic field observed for both liposomes are an indication that part of the Gd complex is interacting with the liposomal membrane. As discussed earlier, the detection of a relaxivity enhancement at 30–40 MHz is an indication of the occurrence of an increased $\tau_1$ with respect to the value found for the free complex. Also, the exchange lifetime of the coordinated water molecule ($\tau_m$) appears slightly increased upon entrapment of the Gd complex in the liposome. This behavior may be accounted for in terms of a slight distortion in the co-ordination cage geometry upon the binding of the lipophilic moiety to the liposome’s membrane.

The relaxivity of DPA-C6-(Gd)DOTAMA (1) loaded liposomes was then measured in the presence of increasing amounts of albumin (HSA) to evaluate whether some amount of 1 could transfer from the liposome to HSA. The Gd-loaded liposomes were challenged with increasing concentrations of albumin (from 0.1 to 0.8 mM), but the relaxation rate ($R_{1\text{rel}}$) at 20 MHz was measured in the presence of increasing amounts of albumin (from 0.1 to 0.8 mM), but the relaxation rate ($R_{1\text{rel}}$) was unchanged. Although the relaxivity of 1 bound to HSA is similar to that of 1 incorporated in the liposome’s membrane, one would expect that the release of 1 from liposomes to HSA causes an overall shift of concentration of 1 either in the aqueous cavity or in the phospholipid bilayer. Such a shift would be related to the amount of added HSA, and it would result in a change of the observed water proton relaxation rate. The observed constancy of $R_1$ clearly indicates that the Gd-complex is not leaving the liposomes in the presence of HSA in the suspending medium. This result is encouraging in the light of future in vivo experiments as DPA-C6-(Gd)DOTAMA loaded liposomes appear to be a stable carrier for improving the blood lifetime of this imaging agent.

### Conclusion

The 2-phenylpyrazolo[1,5-a]pyrimidineacetamide DPA-713 was successfully derivatized and coupled to the DOTA cage. The resulting ligand was complexed with gadolinium. The relaxivity of the obtained Gd-complex was slightly higher ($6.02 \times 10^{-11} \text{ s}^{-1}$ at 20 MHz) than the previously reported ones for analogous Gd-DOTA complexes, which is in accordance with its increased molecular weight. The NMRD profile is consistent with the one expected for a small, fast tumbling gadolinium complex. Interaction with HSA was assessed and a $K_a$ of 1100 M$^{-1}$ was calculated. Incorporation into liposomes displayed a relaxivity ‘hump’ in the NMRD profile, as a demonstration of the formation of a supramolecular adduct. Interestingly, it has been found that the amphiphilic DPA-C6-(Gd)DOTAMA complex can be either incorporated in the liposomal membrane and in the inner aqueous cavity. Overall, the availability of liposomes loaded with this complex is promising for future in vivo studies with increased half-life in blood stream and encourages the task of the slow release of MRI targeting agents.

### Experimental Section

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG-methoxy-2000) were purchased from Avanti Polar Inc. (Alabaster, AL, USA); DOTA(tBu)$_3$ was purchased from CheMatech, and all the other chemicals were purchased from Sigma-Aldrich and used with no further purification. Solvents were stored over molecular sieves and purged with argon before use. Column chromatographies were conducted on silica gel (0.63–20.00 mm, VWR). Thin layer chromatography (TLC) was carried out using aluminum pre-coated plates of silica gel 60 F$_{254}$ (VWR). Compounds were detected using a UV-lamp (254 nm) and by sprinkling the TLC plate with KMnO$_4$ aqueous solution or ninhydrin/ethanol solution and heating.

$^1$H-NMR and $^{13}$C-NMR spectra for characterization of synthesized products were recorded on a Bruker (Wissembourg, France) Avance (400 MHz) apparatus or on a Bruker Avance 600 apparatus using the hydrogenated residue of the deuterated solvents CDCl$_3$ ($\delta = 7.26$ ppm), CD$_2$Cl$_2$ ($\delta = 5.32$ ppm) or CD$_3$OD ($\delta = 3.31$ ppm) for $^1$H-NMR as well as the deuterated solvents CDCl$_3$ ($\delta = 77.2$ ppm), CD$_2$Cl$_2$ ($\delta = 54.0$ ppm) or CD$_3$OD ($\delta = 49.0$ ppm) as an internal standard for $^{13}$C-NMR. Chemical shifts are reported in parts per million (ppm) downfield from TMS. Multiplicities are reported as s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet) and b (broad). The mass spectra (MS) were recorded on a Thermo Electron Ion Trap LCQ Deca XP + spectrometer (positive electrospray ionization (ESI+)) or on a Waters 3100 Single quadrupole mass detector.

The longitudinal water proton relaxation rate was measured by using a Stelar Spinmaster (Stelar, Mede, Pavia, Italy) spectrometer operating at 20 MHz by means of the standard inversion recovery sequence. The temperature was controlled with a Stelar VTC-91 air-flow heater equipped with a copper constantan thermocouple (uncertainty of 0.1 °C). The proton $1/T_1$ NMRD profiles were measured over a continuum of magnetic field strength from 0.00024 to 0.47 T (corresponding to 0.0120 MHz proton Larmor frequency) on a Stelar field-cycling relaxometer. The relaxometer works under complete computer control with an absolute

---

**Table 4.** Best fitting parameters for liposomes LP1 and LP2

|                | $\Delta^2 \times 10^{15}$ | $\tau_1$ (ps) | $\tau_2$ (ps) | $\tau_m$ (μs) | $q$ |
|----------------|-----------------------------|----------------|----------------|---------------|-----|
| LP1            | 1.56                        | 0.15           | 3000           | 0.88          | 1   |
| LP2            | 1.19                        | 7.06           | 2500           | 0.87          | 1   |

**Figure 3.** $1/T_1$ nuclear magnetic resonance dispersion profile of 1 mM aqueous solution of LP1 (●) and LP2 (▲) at 25 °C and pH = 7.4.
uncertainty in $1/T_1$ of ±1%. Data points from 0.47 T (20 MHz) to 1.7 T (70 MHz) were collected on a Stela Spinnaster spectrometer working at variable field.

Liposomes extrusion was carried out with Lipex extruder, Northern Lipids Inc., Canada and the liposomes size measurements were performed on Zetasizer NanoZS Dynamic Light Scattering (Malvern, UK).

Chemistry

N,N-diethyl-2-(2-(4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (DPA-OH). Synthesized according to Ref. 17.

$R_f$ (CH$_3$Cl$_2$/CH$_3$OH 95/5 v/v): 0.39. $^1$H-NMR (CD$_2$Cl$_2$, 400 MHz)  $\delta$ 7.75 (2H, d, $J$ = 8.8 Hz, Ar), 6.99 (2H, d, $J$ = 8.8 Hz, Ar), 6.54 (1H, s, Ar), 3.88 (2H, s, CH$_2$CO), 3.85 (3H, s, OCH$_3$), 3.51 (2H, q, $J$ = 7.2 Hz, NCH$_2$CH$_3$), 3.39 (2H, q, $J$ = 7.2 Hz, NCH$_2$CH$_3$), 2.72 (3H, s, ArCH$_3$), 2.53 (3H, s, ArCH$_3$), 1.22 (3H, t, $J$ = 7.2 Hz, NCH$_2$CH$_3$), 1.11 (3H, t, $J$ = 7.2 Hz, NCH$_2$CH$_3$). $^{13}$C-NMR (CD$_2$Cl$_2$, 100 MHz)  $\delta$ 170.3 [C, CO], 160.4 [C, Ar], 158.1 [C, Ar], 159.5 [C, Ar], 148.3 [C, Ar], 145.3 [C, Ar], 130.2 [2 × CH, Ar], 127.0 [C, Ar], 114.4 [2 × CH, Ar], 108.7 [CH, Ar], 101.3 [C, Ar], 55.8 [CH$_3$, OCH$_3$], 42.8 [CH$_2$, NCH$_2$CH$_3$], 41.0 [CH$_3$, NCH$_2$CH$_3$], 28.6 [CH$_2$, COCH$_3$], 24.9 [CH$_2$, ArCH$_3$], 17.1 [CH$_2$, ArCH$_3$], 14.7 [CH$_3$, NCH$_2$CH$_3$], 13.4 [CH$_3$, NCH$_2$CH$_3$]. MS ESI + ($m/z$) 367 [M + H]$^+$.  

N,N-diethyl-2-((2-(4-hydroxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)amino)hexyl 4-methylbenzenesulfonate (DPA-OH, 2). Synthesized according to Ref. 20.

$R_f$ (CH$_3$Cl$_2$/CH$_3$OH 92/8 v/v): 0.41. $^1$H-NMR (CD$_2$Cl$_2$, 400 MHz)  $\delta$ 7.56 (2H, d, $J$ = 8.4 Hz, Ar), 6.82 (2H, d, $J$ = 8.4 Hz, Ar), 6.55 (1H, s, Ar), 3.90 (2H, s, CH$_2$CO), 3.47 (2H, q, $J$ = 7.2 Hz, NCH$_2$CH$_3$), 3.37 (2H, q, $J$ = 7.2 Hz, NCH$_2$CH$_3$), 2.71 (3H, s, ArCH$_3$), 2.52 (3H, s, ArCH$_3$), 2.21 (1H, bs, OH), 1.18 (3H, t, $J$ = 7.2 Hz, NCH$_2$CH$_3$), 1.09 (3H, t, $J$ = 7.2 Hz, NCH$_2$CH$_3$). $^{13}$C-NMR (CD$_2$Cl$_2$, 100 MHz)  $\delta$ 171.2 [C, CO], 158.7 [C, Ar], 158.2 [C, Ar], 155.8 [C, Ar], 148.2 [C, Ar], 145.8 [C, Ar], 130.4 [2 × CH, Ar], 125.4 [C, Ar], 116.0 [2 × CH, Ar], 108.9 [CH, Ar], 100.8 [C, Ar], 43.0 [CH$_3$, NCH$_2$CH$_3$], 41.4 [CH$_2$, NCH$_2$CH$_3$], 28.7 [CH$_2$, COCH$_3$], 24.7 [CH$_2$, ArCH$_3$], 17.2 [CH$_2$, ArCH$_3$], 14.4 [CH$_3$, NCH$_2$CH$_3$], 13.3 [CH$_3$, NCH$_2$CH$_3$]. MS ESI + ($m/z$) 353 [M + H]$^+$.  

tert-Butyl (6-(4-((3-(2-diethylamino)-2-oxoethyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)phenoxy)ethyl)carbamate (3). Step 1. tert-butyl(2-(4-aminophenyl)oxy)ethyl 4-methylbenzenesulfonate) synthesis. Under argon atmosphere, 6-(Boc-amino)hexyl 4-methylbenzenesulfonate (1.47 g, 4.00 mmol) was dissolved in 50 ml of dichloromethane and trifluoroacetic acid (10 ml, 2 ml) was added. The solution was stirred at room temperature overnight. The reaction was then evaporated to dryness, and the residue was partitioned between a saturated aqueous solution of K$_2$CO$_3$ and EtOAc. The organic layer was collected, and the aqueous phase was washed twice with EtOAc. The resulting organic layers were combined to the first one. The combined organic layers were washed with brine, dried over Na$_2$SO$_4$, filtered and concentrated under reduced pressure. The crude was purified on silica gel (CH$_3$Cl/CH$_3$OH 90/10) to afford the desired product (1.17 g, 3.33 mmol) was dissolved in 50 ml of dichloromethane and trifluoroacetic acid (10 ml, 132 mmol) was added. The solution was stirred at room temperature overnight. The reaction was then evaporated to dryness, and the residue was dissolved in CH$_2$Cl$_2$ and HCl 0.1 M aqueous solution (150 ml) and extracted twice with EtOAc (2 × 200 ml). The combined organic layers were washed twice (2 × 200 ml) with brine, dried over Na$_2$SO$_4$, filtered and concentrated under reduced pressure.
room temperature for 24 h. The reaction was partitioned between water and EtOAc. The aqueous phase was acidified to pH 5–6, and extracted twice with EtOAc. The collected organic layers were washed once with water and once with brine, dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified on silica gel using CH₂Cl₂/CH₃OH 95/5 v/v as eluent; yielding the desired product 5 as a yellow solid (0.55 g, 80%). 1H NMR (CD₃OD, 600 MHz) δ 7.62 (2H, d, J = 6.8 Hz, CH₂NH-DOTA(tBu)₃), 5.96 (2H, d, J = 7.2 Hz, NCH₃), 3.22 (2H, t, J = 7.2 Hz, NCH₂), 2.73 (3H, s, CH₃), 1.81 (2H, m, CH₂NH), 1.28 (3H, t, J = 7.6 Hz, ArOCH₂), 3.54 (2H, m, NC₂HCH₂), 3.30 (8H, b, 3CH₂), 2.56 (8H, b, 4CH₂), 1.60–1.35 (6H, m, 3CH₂), 1.24 (3H, t, J = 7.2 Hz, NCH₂), 1.12 (3H, t, J = 7.2 Hz, NCH₃), 1.3C NMR (CD₃OD, 150 MHz) δ 174.4 [2 × C, C = O], 173.1 [C, C = O], 172.3 [C, C = O], 161.1 [C, Ar], 156.0 [C, Ar], 148.9 [C, Ar], 147.0 [C, Ar], 131.0 [2 × CH, Ar], 126.9 [C, Ar], 115.5 [2 × CH, Ar], 109.7 [CH, Ar], 101.5 [C, Ar], 82.8 [3 × C, CH₂], 69.8 [CH₂, ArOCH₂], 57.2 [CH₂, NCH₃CON], 56.8 [CH₂, NCH₂COOtBu], 56.3 [2 × CH₂, NCH₂COOtBu], 55.1 [8 × CH₂, b, CH₃], 43.6 [CH₂, NCH₃CH₂], 42.0 [CH₂, NCH₃CH₃], 40.2 [CH₃, CH₃], 38.0 [CH₃, CH₃], 28.9 [CH₃], 28.5 [9 × CH₃, 3 × t-Bu], 27.8 [CH₃], 27.0 [CH₃], 24.2 [CH₃, ArCH₂], 16.9 [CH₃, ArCH₂], 14.3 [CH₃, NCH₃CH₂], 13.3 [CH₃, NCH₂CH₃]. MS ESI+(m/z) 1028 [M + Na]+, 838 [M + H]+, 420 [M + 2H]/2+, 280 [M + 3H]/3+. [6] 2,2′,6,2′-terpyridine (3) was then hydrated at 55°C with 1.45 ml of saline buffer (HEPES/NaCl mole ratio 1/6.5) to obtain a total lipid amount of 30 mg/ml. The resulting suspension of multilamellar vesicles was extruded three times through polycarbonate filters of 400 nm and five times through 200 nm filters. The final suspension was then purified by exhaustive dialysis into water at 4°C in saline buffer.

Liposomes preparation, general procedure

Large unilamellar vesicles (LUV) were prepared following the thin film hydration method.[14] Briefly, the lipids were dissolved in chloroform or chloroform/methanol solution, and the organic solution was slowly evaporated until the thin film was formed. The film was then hydrated at 55°C with 1.45 ml of saline buffer and then was extruded. The mean hydrodynamic diameter was 151 nm with a polydispersity index (PDI) of 0.07.

Liposomes were characterized by dynamic light scattering (Zetasizer NanoZS, Malvern, UK) in order to assess the mean hydrodynamic size and the polydispersity of the system.

Acknowledgements

This work was supported in part by intramural programs, as well as the FP6 European Networks of Excellence EMIL (Grant LSHC-CT-2004-503569) and DiMi (Grant LSHB-CT-2005-512146), and more recently the European Union’s Seventh Framework Programme (FP7/2007-2013) INMIND (Grant agreement no. HEALTH-F2-2011-278850). Part of the work presented was also carried out in the frame of COST TD1004 Action (‘Theranostics’). The authors also wish to thank Dr Dirk Roeda for proofreading the manuscript and suggesting linguistic corrections.

References

[1] V. Papadopoulos, M. Baraldi, T. B. Gualtieri, T. B. Knudsen, J. J. Lapacere, P. Lindemann, M. D. Norenberg, D. Nutt, A. Weizman, M. R. Zhang, M. Gavish. Trends Pharmacol. Sci. 2006, 27, 402–409.
[2] R. Rupprecht, V. Papadopoulos, G. Rammes, T. C. Baghie, J. Fan, N. Akula, G. Groyer, A. Adams, M. Schumacher. Nat. Rev. Drug Discov. 2010, 9, 971–988.
[3] V. Papadopoulos, J. Liu, M. Culty. Mol. Cell. Endocrinol. 2007, 266, 59–67.
[4] P. Casellas, S. Gallegue, A. S. Basile. Neurochem. Int. 2002, 40, 475–486.
[5] M. Gavish, I. Bachman, R. Shoukrun, Y. Katz, L. Veenman, G. Weisinger, A. Weizman. Pharmacol. Rev. 1999, 51, 629–650.
[6] R. R. Anholt, K. M. Murphy, G. E. Mack, S. H. Snyder. J. Neurosci. 1984, 4, 593–603.
[7] G. T. Bolger, E. Mezey, J. Cott, B. A. Weissman, S. M. Paul, P. Skolnick. Eur. J. Pharmacol. 1984, 105, 143–148.
[8] D. Decaydaud, M. Castedo, F. Nematì, A. Beurdeley-Thomas, G. De Pinieux, A. Caron, P. Pouillart, J. Wijdenes, D. Rouillard, G. Kroemer, M. F. Poupon. Cancer Res. 2002, 62, 1388–1393.
